The News
The FDA Just Reset the Conversation on HRT
In late 2025, the FDA announced it would remove the boxed warning long printed on many hormone replacement therapy (HRT) products used for menopause. The boxed warning is the agency's most serious label alert, and for more than two decades it shaped how women and clinicians viewed hormone therapy.
For many women, that warning was the reason they were never offered HRT, or quietly stopped it. The updated position reflects a growing scientific consensus that the original warnings overstated risk for many women, particularly those who begin therapy near the onset of menopause.
At Protocol Health, our family-owned, physician-led team in Scarsdale has followed this evidence closely. Below, we break down what changed, why it matters, and how individualized, lab-informed care fits into the new landscape for women across Westchester and the NY, NJ, CT, FL, and CA.
Explore Hormone Therapy for WomenQuick Answer
What did the FDA actually change?
The FDA moved to remove the boxed ("black box") warning from certain systemic estrogen and estrogen-containing menopause products. The agency's position is that the strongest-tier warning no longer reflects the balance of evidence for many women who use HRT to manage menopausal symptoms.
This does not mean hormone therapy is risk-free or right for everyone. It means the labeling is being brought closer in line with current research, so decisions can be made on individual risk rather than a one-size-fits-all alarm.
The practical takeaway: HRT deserves a fresh, informed conversation with a qualified provider, not automatic avoidance based on a warning written for a different era.
The History
Why were the warnings there in the first place?
The warnings trace back to the Women's Health Initiative (WHI), a large study whose early 2002 results were widely reported as showing that hormone therapy raised the risk of breast cancer, heart disease, and stroke. Headlines drove millions of women off HRT almost overnight.
In the years since, researchers have revisited that data. A key idea is the "timing hypothesis": the average WHI participant was in her early-to-mid 60s, often more than a decade past menopause, which is not when most women start therapy for symptoms.
Later analyses suggested that for many women who begin HRT closer to menopause, typically under 60 or within ten years of their final period, the benefit-risk picture can look meaningfully different from what the original headlines implied. The label, however, lagged behind the evolving science for years.
What Changed
How the evidence evolved
Menopause specialists and major medical societies have argued for some time that a blanket boxed warning discouraged appropriate care and contributed to years of undertreated menopausal symptoms, including hot flashes, night sweats, sleep disruption, mood changes, and genitourinary symptoms.
Research now suggests that route of delivery and formulation matter. Transdermal estrogen (patches, creams, gels) and individualized dosing are often discussed differently from the older oral regimens studied decades ago, though every option carries its own considerations that a provider must weigh.
The FDA's move acknowledges this nuance. Rather than a single warning applied broadly, the emphasis shifts toward individualized assessment, which is how modern hormone care should work.
Why It Matters
What this means for women considering HRT
For women who have hesitated because of the old warning, this is an invitation to have an evidence-based conversation rather than a reason to start therapy on impulse. HRT may help many women manage disruptive menopausal symptoms and support quality of life, but suitability is always individual and determined with a provider.
It also matters for how care is delivered. The change reinforces that hormone therapy should be guided by your personal and family history, current labs, symptoms, and goals, not by a headline or a decades-old assumption.
If you stopped HRT years ago, or were never offered it, this can be a reasonable moment to revisit the question with a physician who treats hormone health as a core specialty rather than an afterthought.
Candidacy
Who is typically a candidate for hormone therapy?
Hormone replacement therapy is most often considered for women experiencing menopausal or perimenopausal symptoms such as hot flashes, night sweats, sleep disturbance, mood shifts, brain fog, low libido, or vaginal and urinary symptoms. Women within roughly ten years of their final period or under 60 are frequently part of the conversation, though age alone is never the sole factor.
Candidacy depends on your full clinical picture: personal and family history (including breast cancer, blood clots, and cardiovascular disease), current symptoms, and lab results. Some women are better served by non-hormonal approaches, and a good provider will say so.
The only way to know whether HRT fits you is an individualized evaluation. Our Female Hormone & Longevity Assessment is designed for exactly this kind of thorough, lab-informed review.
Safety
Is hormone replacement therapy safe?
No medical therapy is entirely without risk, and HRT is no exception. Potential considerations can include effects on blood clots, breast tissue, and cardiovascular health, and these vary by a woman's age, health history, formulation, and how therapy is delivered.
The updated FDA stance does not erase these considerations; it corrects an overstatement so that real risks can be weighed honestly against potential benefits for each individual. That is a more accurate foundation for a decision, not a reason to skip caution.
This is why physician supervision, appropriate lab work, and ongoing monitoring matter. Therapy is reviewed over time and adjusted as needed, and any new symptoms are evaluated promptly. This article is educational and not a substitute for personalized medical advice.
What to Expect
What the process looks like at Protocol Health
Care begins with a conversation and a comprehensive assessment of your symptoms, history, and goals. From there, we typically order lab work, which may include hormone panels and other markers, to build an accurate picture before recommending anything.
If hormone therapy is appropriate, your physician discusses options, which may include estrogen creams or gels, patches, vaginal estrogen, oral progesterone, or low-dose testosterone for women, and explains the reasoning behind each choice. Dosing is individualized, and you are monitored and adjusted over time.
Whether you are in Scarsdale, elsewhere in Westchester, or across the NY, NJ, CT, FL, and CA, care can be delivered in person or via telehealth, with the same physician-led attention to detail.
Our Approach
Physician-led hormone care, built around you
Protocol Health is a family-owned, physician-led clinic where hormone optimization is a core focus, not a side offering. Our clinical team treats menopause and hormone health as an individualized, data-driven discipline, combining careful labs, current evidence, and ongoing follow-up.
The FDA's decision to remove outdated warnings is a welcome step toward the kind of nuanced, personalized care we already practice. It gives women room to ask better questions, and it gives clinicians a more honest starting point.
If you have been curious about HRT, or set it aside because of old fears, we would be glad to help you understand your options based on your body and your goals, not a warning label from another era.
FAQ
Frequently Asked Questions
Did the FDA say hormone replacement therapy is completely safe now?
No. The FDA moved to remove the strongest-tier boxed warning because it overstated risk for many women, but hormone therapy still carries considerations that vary by individual. The change supports informed, individualized decisions rather than declaring HRT risk-free. A qualified provider should always assess your personal history and labs first.
Why were women told to avoid HRT for so long?
Early 2002 results from the Women's Health Initiative were widely reported as showing increased risks of breast cancer, heart disease, and stroke, which drove millions of women off therapy. Later analyses found the study population was older and further from menopause than typical HRT users, which changed the interpretation. The labeling took years to catch up with that evolving evidence.
Is it too late to start HRT if I went through menopause years ago?
Not necessarily, but timing is one important factor among many. Research suggests the benefit-risk picture is often most favorable for women who begin closer to menopause, generally under 60 or within about ten years of their final period. The right answer depends on your full clinical picture, which is best determined through an individualized evaluation with a physician.
What types of hormone therapy are available for women?
Options can include estrogen creams or gels, estrogen patches, vaginal estrogen, oral progesterone, and low-dose testosterone for women, among others. The best choice depends on your symptoms, history, and goals, and is determined with your physician. Dosing is individualized and monitored over time.
Do I need lab work before starting hormone therapy?
In most cases, yes. Lab work helps build an accurate picture of your hormone levels and overall health before any therapy is recommended, and supports safe monitoring afterward. At Protocol Health, hormone care is lab-informed and physician-supervised from the start.
Can I do this through telehealth if I am not in Scarsdale?
Often, yes. Protocol Health serves patients across the NY, NJ, CT, FL, and CA, and many aspects of hormone care can be handled via telehealth, with in-person options available when appropriate. Your physician will advise on what makes sense for your situation.
Explore